Results 181 to 190 of about 427,029 (392)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia [PDF]

, 1996
David Van Den Berg, Maija Wessman, Lesley Murray, Junming Tong, B Chen, S Chen, Débora Simonetti, Justin King, Glenn Yamasaki, R DiGiusto, David P. Gearing, Christopher L. Reading   +11 more
openalex   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Leukemia and risk of stroke: a Mendelian randomization analysis

BMC Neurology
Background Observational studies suggest an association between leukemia and stroke, but causality remains unclear. Certain leukemia types may increase stroke risk, but variations exist in stroke and mortality rates across leukemia subtypes.
Xiaoyao Yi, Jingrui Zhu, Xiang Zhang, Ning Huang, Yuan Cheng   +4 more
doaj   +1 more source

Pregnancy Outcome in Chronic Myeloid Leukemia Patients on Imatinib Therapy

, 2012
S. Shankar, S. Dasgupta, S. Mukhopadhyay, Deepankar Bhattacharya, F.H. Gharami, S. Koner, Uttam Kumar Roy, Jayasri Basak, Ashis Mukhopadhyay   +8 more
openalex   +1 more source

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

New England Journal of Medicine, 2001
B. Druker, C. Sawyers, H. Kantarjian, D. Resta, Sofia Fernandes Reese, J. Ford, R. Capdeville, M. Talpaz   +7 more
semanticscholar   +1 more source

Nanogel‐Mediated Immunotherapy to Tackle Cancer and Inflammatory Diseases

ChemistryEurope, EarlyView.
Nanogels formed through self‐assembly, microemulsion, or precipitation polymerization method enable precise delivery of immunotherapeutic factors and immune cell targeting, thus effectively modulating immune responses. This review highlights recent advances in stimuli‐responsive nanogel design, underlying mechanisms, and their potentials to tackle ...
Ziwen Zhang, Jinxia Wang, Guang‐Zhi Jin, István Bányai, Dzmitry Shcharbin, Ivan Stoikov, Mingwu Shen, Xiangyang Shi   +7 more
wiley   +1 more source

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

Drug Design, Development and Therapy, 2016
Dilek Keskin, Sevil Sadri, Ahmet Emre Eskazan Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey Abstract: Dasatinib is one of the second-generation tyrosine kinase inhibitors
Keskin D, Sadri S, Eskazan AE
doaj  

Single amino acid–based PROTACs trigger degradation of the oncogenic kinase BCR–ABL in chronic myeloid leukemia (CML) [PDF]

, 2023
Jianchao Zhang, Caibing Ma, Yongjun Yu, Chaowei Liu, Lijing Fang, Hai Rao   +5 more
openalex   +1 more source